Cargando…

Development of mobile technologies for the prevention of cervical cancer in Santiago, Chile study protocol: a randomized controlled trial

BACKGROUND: In Chile, more than 500 women die every year from cervical cancer, and a majority of Chilean women are not up-to-date with their Papanicolau (Pap) test. Mobile health has great potential in many health areas, particularly in health promotion and prevention. There are no randomized contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Momany, McKenzie C., Martinez-Gutierrez, Javiera, Soto, Mauricio, Capurro, Daniel, Ciampi, Francis, Thompson, Beti, Puschel, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729241/
https://www.ncbi.nlm.nih.gov/pubmed/29237420
http://dx.doi.org/10.1186/s12885-017-3870-8
_version_ 1783286152658157568
author Momany, McKenzie C.
Martinez-Gutierrez, Javiera
Soto, Mauricio
Capurro, Daniel
Ciampi, Francis
Thompson, Beti
Puschel, Klaus
author_facet Momany, McKenzie C.
Martinez-Gutierrez, Javiera
Soto, Mauricio
Capurro, Daniel
Ciampi, Francis
Thompson, Beti
Puschel, Klaus
author_sort Momany, McKenzie C.
collection PubMed
description BACKGROUND: In Chile, more than 500 women die every year from cervical cancer, and a majority of Chilean women are not up-to-date with their Papanicolau (Pap) test. Mobile health has great potential in many health areas, particularly in health promotion and prevention. There are no randomized controlled trials in Latin America assessing its use in cervical cancer screening. The ‘Development of Mobile Technologies for the Prevention of Cervical Cancer in Santiago, Chile’ study aims to determine the efficacy of a text-message intervention on Pap test adherence among Chilean women in the metropolitan region of Santiago. METHODS/DESIGN: This study is a parallel randomized-controlled trial of 400 Chilean women aged 25–64 who are non-adherent with current recommendations for Pap test screening. Participants will be randomly assigned to (1) a control arm (usual care) or (2) an intervention arm, where text and voice messages containing information and encouragement to undergo screening will be sent to the women. The primary endpoint is completion of a Pap test within 6 months of baseline assessment, as determined by medical record review at community-based clinics. Medical record reviewers will be blinded to randomization arms. The secondary endpoint is an evaluation of the implementation and usability of the text message intervention as a strategy to improve screening adherence. DISCUSSION: This intervention using mobile technology intends to raise cervical cancer screening adherence and compliance among a Chilean population of low and middle-low socioeconomic status. If successful, this strategy may reduce the incidence of cervical cancer. TRIAL REGISTRATION: Clinicaltrials.gov NCT02376023 Registered 2/17/2015. First participant enrolled Feb 22nd 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-017-3870-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5729241
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57292412017-12-18 Development of mobile technologies for the prevention of cervical cancer in Santiago, Chile study protocol: a randomized controlled trial Momany, McKenzie C. Martinez-Gutierrez, Javiera Soto, Mauricio Capurro, Daniel Ciampi, Francis Thompson, Beti Puschel, Klaus BMC Cancer Study Protocol BACKGROUND: In Chile, more than 500 women die every year from cervical cancer, and a majority of Chilean women are not up-to-date with their Papanicolau (Pap) test. Mobile health has great potential in many health areas, particularly in health promotion and prevention. There are no randomized controlled trials in Latin America assessing its use in cervical cancer screening. The ‘Development of Mobile Technologies for the Prevention of Cervical Cancer in Santiago, Chile’ study aims to determine the efficacy of a text-message intervention on Pap test adherence among Chilean women in the metropolitan region of Santiago. METHODS/DESIGN: This study is a parallel randomized-controlled trial of 400 Chilean women aged 25–64 who are non-adherent with current recommendations for Pap test screening. Participants will be randomly assigned to (1) a control arm (usual care) or (2) an intervention arm, where text and voice messages containing information and encouragement to undergo screening will be sent to the women. The primary endpoint is completion of a Pap test within 6 months of baseline assessment, as determined by medical record review at community-based clinics. Medical record reviewers will be blinded to randomization arms. The secondary endpoint is an evaluation of the implementation and usability of the text message intervention as a strategy to improve screening adherence. DISCUSSION: This intervention using mobile technology intends to raise cervical cancer screening adherence and compliance among a Chilean population of low and middle-low socioeconomic status. If successful, this strategy may reduce the incidence of cervical cancer. TRIAL REGISTRATION: Clinicaltrials.gov NCT02376023 Registered 2/17/2015. First participant enrolled Feb 22nd 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-017-3870-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-12-13 /pmc/articles/PMC5729241/ /pubmed/29237420 http://dx.doi.org/10.1186/s12885-017-3870-8 Text en © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Momany, McKenzie C.
Martinez-Gutierrez, Javiera
Soto, Mauricio
Capurro, Daniel
Ciampi, Francis
Thompson, Beti
Puschel, Klaus
Development of mobile technologies for the prevention of cervical cancer in Santiago, Chile study protocol: a randomized controlled trial
title Development of mobile technologies for the prevention of cervical cancer in Santiago, Chile study protocol: a randomized controlled trial
title_full Development of mobile technologies for the prevention of cervical cancer in Santiago, Chile study protocol: a randomized controlled trial
title_fullStr Development of mobile technologies for the prevention of cervical cancer in Santiago, Chile study protocol: a randomized controlled trial
title_full_unstemmed Development of mobile technologies for the prevention of cervical cancer in Santiago, Chile study protocol: a randomized controlled trial
title_short Development of mobile technologies for the prevention of cervical cancer in Santiago, Chile study protocol: a randomized controlled trial
title_sort development of mobile technologies for the prevention of cervical cancer in santiago, chile study protocol: a randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729241/
https://www.ncbi.nlm.nih.gov/pubmed/29237420
http://dx.doi.org/10.1186/s12885-017-3870-8
work_keys_str_mv AT momanymckenziec developmentofmobiletechnologiesforthepreventionofcervicalcancerinsantiagochilestudyprotocolarandomizedcontrolledtrial
AT martinezgutierrezjaviera developmentofmobiletechnologiesforthepreventionofcervicalcancerinsantiagochilestudyprotocolarandomizedcontrolledtrial
AT sotomauricio developmentofmobiletechnologiesforthepreventionofcervicalcancerinsantiagochilestudyprotocolarandomizedcontrolledtrial
AT capurrodaniel developmentofmobiletechnologiesforthepreventionofcervicalcancerinsantiagochilestudyprotocolarandomizedcontrolledtrial
AT ciampifrancis developmentofmobiletechnologiesforthepreventionofcervicalcancerinsantiagochilestudyprotocolarandomizedcontrolledtrial
AT thompsonbeti developmentofmobiletechnologiesforthepreventionofcervicalcancerinsantiagochilestudyprotocolarandomizedcontrolledtrial
AT puschelklaus developmentofmobiletechnologiesforthepreventionofcervicalcancerinsantiagochilestudyprotocolarandomizedcontrolledtrial